Mar 09, 2020 6:30am EDT Matinas BioPharma Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights
Mar 05, 2020 7:00am EST Matinas BioPharma Announces Initiation of ENHANCE-IT Study of MAT9001 Against Vascepa®
Mar 04, 2020 7:00am EST Matinas BioPharma Appoints James A. Underberg, M.D. to its MAT9001 Scientific Advisory Board
Feb 24, 2020 4:15pm EST Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2019 Operational and Financial Results on March 9, 2020
Feb 19, 2020 7:00am EST Matinas BioPharma Announces DSMB Approval to Commence Part 2 of EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis
Dec 12, 2019 7:00am EST Matinas BioPharma Announces Feasibility Evaluation with Third Large Biopharmaceutical Company for the Formulation of Compounds Utilizing LNC Delivery Platform
Nov 18, 2019 7:30am EST Matinas BioPharma to Present at the 31st Annual Piper Jaffray Healthcare Conference
